•  
     
     
    Type Size
     

    Osteoprotection by semaphorin 3A

    The authors show that semaphorin 3A (Sema3A) both suppresses osteoclastic bone resorption and increases osteoblastic bone formation. The binding of Sema3A to neuropilin-1 (Nrp1) inhibited receptor activator of nuclear factor-κB ligand (RANKL)-induced osteoclast differentiation by inhibiting the immunoreceptor tyrosine-based activation motif (ITAM) and RhoA signalling pathways. These results imply that semaphorin 3A has potential as a therapeutic agent for metabolic bone diseases.

    http://www.nature.com/nature/journal/v485/n7396/full/nature11000.html

    Hayashi M, Nakashima T, Taniguchi M, Kodama T, Kumanogoh A, Takayanagi H.